What is the partnership roadmap for pharma and digital therapeutics (DTx) companies collaborations?
The number of partnerships between DTx and pharma have accelerated in recent years and yet we are still in the exploratory phase of this relationship. Successful partnerships have shown us the potential benefits of a DTx-pharma relationship, but there are still numerous failures within collaborations that also must be examined. Given the cultural clash, DTx and pharma collaborations need to have a clear roadmap from the beginning to ensure all teams are aligned and go in the same direction, and thus, prevent shortcomings seen before. Join this session to have a peer-to-peer conversation about the partnership roadmap for pharma-DTx collaborations:
Once a deal between the DTx and pharma company is closed and we have a clear roadmap on the table, what comes next? How do we ensure the partnership will succeed? How flexible do we need to be along the journey?
What can we learn from unsuccessful partnerships to help us build better partnership roadmaps?
How can we build the internal operations that will support partnerships with DTx companies? Who within the pharma company needs to lead these operational changes?
How can pharma companies reach parallel paths of procurement, legal, data privacy and compliance to make a partnership work?